Source: Eur Respir Rev, 31 (163) 210241; 10.1183/16000617.0241-2021



Rating:

Share or cite this content

Citations should be made in the following way:
Holly R. Keir, James D. Chalmers. Neutrophil extracellular traps in chronic lung disease: implications for pathogenesis and therapy. Eur Respir Rev, 31 (163) 210241; 10.1183/16000617.0241-2021

Member's Comments

No comment yet.

Related content which might interest you: Role of the inflammasome in the pathophysiology of antisynthetase-associated interstitial lung disease. Source: Virtual Congress 2021 – Clinical evolution, management and outcomes of patients with rare diffuse parenchymal lung diseases Year: 2021 Role of neutrophil mechanisms of inflammation in pathogenesis of different types of pulmonary fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 459s Year: 2003 Neutrophil extracellular traps (NETs) in COPD: A potential novel mechanism for host damage in acute exacerbations Source: International Congress 2015 – Cellular and molecular mechanisms of COPD and emphysema Year: 2015 Host–microbe cross-talk in the lung microenvironment: implications for understanding and treating chronic lung disease Source: Eur Respir J, 56 (2) 1902320; 10.1183/13993003.02320-2019 Year: 2020 Erythromycin inhibits neutrophil extracellular traps in smoking-related chronic pulmonary inflammation Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019 Pathogenesis of idiopathic pulmonary fibrosis: role of neutrophil inflammation Source: Eur Respir J 2006; 28: Suppl. 50, 102s Year: 2006 Prevalence and trafficking of circulating fibrocytes in smoking-related fibrogenic lung diseases Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015 Predictive role of neutrophil elastase in the follow-up of patients with interstitial lung diseases Source: Eur Respir J 2001; 18: Suppl. 33, 409s Year: 2001 A?-Val360: a marker of neutrophil elastase and COPD disease activity Source: Eur Respir J 2013; 41: 31-38 Year: 2013 Cellular interactions in the pathogenesis of interstitial lung diseases Source: Eur Respir Rev 2015; 24: 102-114 Year: 2015 Revisiting the role of pulmonary surfactant in chronic inflammatory lung diseases and environmental exposure Source: Eur Respir Rev, 30 (162) 210077; 10.1183/16000617.0077-2021 Year: 2021 Neutrophil elastase in children with chronic lung diseases Source: Annual Congress 2008 - Cystic fibrosis: a disease with many aspects Year: 2008 Macrophage dysfunction in the pathogenesis and treatment of asthma Source: Eur Respir J, 50 (3) 1700196; 10.1183/13993003.00196-2017 Year: 2017 Nintedanib reduces fibrotic markers in the lung in a model of rheumatoid arthritis associated interstitial lung disease Source: International Congress 2016 – ILD pathogenesis Year: 2016 Sputum protein profiles for monitoring lung pathophysiology in chronic lung diseases Source: Annual Congress 2012 - Recent progress in mechanisms and diagnostics of COPD and asthma Year: 2012 Effects of a neutrophil elastase inhibitor against mediators of acute exacerbation of pulmonary fibrosis: a new therapeutic strategy Source: Annual Congress 2008 - New therapeutic strategies in idiopathic pulmonary fibrosis Year: 2008 Role of systemic inflammation mediated by IL-6 and TNF-alpha cytokines in chronic obstructive pulmonary disease and its progression: A three year follow up study Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases Year: 2013 Neutrophil elastase levels is higher in patients with lung cancer than chronic obstructive pulmonary disease Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer Year: 2011 Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases Source: Eur Respir Rev, 28 (153) 190109; 10.1183/16000617.0109-2019 Year: 2019